Clinical Trial Update: Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

View source ↗

Summary

The document provides an update on an AstraZeneca-sponsored clinical trial evaluating ravulizumab for generalized myasthenia gravis. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Ravulizumab (Ultomiris) (ravulizumab-cwvz)

Snippet

Sponsor: AstraZeneca | Conditions: Myasthenia Gravis, Generalized | Status: RECRUITING